title: [Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].
abstract: Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential). Significant reduction of annual relapse rate for 70.3%, stabilization of neurological status and benign safety profile were demonstrated during Copaxone treatment. Practical recommendations for Copaxone use are given.
authors.forename: I A
authors.initials: IA
authors.lastname: Zavalishin
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
authors.forename: N N
authors.initials: NN
authors.lastname: Iakhno
authors.forename: M A
authors.initials: MA
authors.lastname: Ronkin
authors.forename: T E
authors.initials: TE
authors.lastname: Shmidt
authors.forename: T L
authors.initials: TL
authors.lastname: Demina
authors.forename: A I
authors.initials: AI
authors.lastname: Kugoev
authors.forename: L S
authors.initials: LS
authors.lastname: Adarcheva
authors.forename: A S
authors.initials: AS
authors.lastname: Niiazbekova
authors.forename: M N
authors.initials: MN
authors.lastname: Zakharova
authors.forename: A B
authors.initials: AB
authors.lastname: Peresedova
authors.forename: G G
authors.initials: GG
authors.lastname: Toropina
authors.forename: L A
authors.initials: LA
authors.lastname: Klishevskaia
authors.forename: I M
authors.initials: IM
authors.lastname: Maksimenko
authors.forename: M V
authors.initials: MV
authors.lastname: Krotenkova
authors.forename: S N
authors.initials: SN
authors.lastname: Konovalov
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Rebrova
authors.forename: T D
authors.initials: TD
authors.lastname: Zhuchenko
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate